Patient-derived tumour xenografts as models for oncology drug development (original) (raw)

• Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424–1431 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Daniel, V. C. et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69, 3364–3373 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Giovanella, B. C. et al. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science 246, 1046–1048 (1989).
  Article CAS PubMed Google Scholar
• Houghton, J. A., Maroda, S. J. Jr, Phillips, J. O. & Houghton, P. J. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res. 41, 144–149 (1981).
  CAS PubMed Google Scholar
• Houghton, J. A. & Taylor, D. M. Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br. J. Cancer 37, 213–223 (1978).
  Article CAS PubMed PubMed Central Google Scholar
• Jin, K. et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin. Transl. Oncol. 12, 473–480 (2010).
  Article PubMed Google Scholar
• Morton, C. L. & Houghton, P. J. Establishment of human tumor xenografts in immunodeficient mice. Nat. Protoc. 2, 247–250 (2007).
  Article CAS PubMed Google Scholar
• Rubio-Viqueira, B. & Hidalgo, M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin. Pharmacol. Ther. 85, 217–221 (2009).
  Article CAS PubMed Google Scholar
• Sausville, E. A. & Burger, A. M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66, 3351–3354 (2006).
  Article CAS PubMed Google Scholar
• Jin, K. et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin. Transl. Oncol. 12, 473–480 (2010).
  Article PubMed Google Scholar
• Rubio-Viqueira, B. et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12, 4652–4661 (2006).
  Article CAS PubMed Google Scholar
• John, T. et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin. Cancer Res. 17, 134–141 (2011).
  Article CAS PubMed Google Scholar
• Merk, J., Rolff, J., Becker, M., Leschber, G. & Fichtner, I. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur. J. Cardiothorac. Surg. 36, 454–459 (2009).
  Article PubMed Google Scholar
• Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477–6489 (2005).
  Article CAS PubMed Google Scholar
• Simpson-Abelson, M. R. et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rγnull mice. J. Immunol. 180, 7009–7018 (2008).
  Article CAS PubMed Google Scholar
• Pitts, T. M. et al. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin. Cancer Res. 16, 3193–3204 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Sanz, L. et al. Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Lab. Invest. 89, 91–97 (2009).
  Article CAS PubMed Google Scholar
• Gray, D. R. et al. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res. 64, 1712–1721 (2004).
  Article CAS PubMed Google Scholar
• Smith, V., Wirth, G. J., Fiebig, H. H. & Burger, A. M. Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genomics Proteomics 5, 263–273 (2008).
  CAS PubMed Google Scholar
• Garrido-Laguna, I. et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 17, 5793–5800 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Fichtner, I. et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 14, 6456–6468 (2008).
  Article CAS PubMed Google Scholar
• Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Linnebacher, M. et al. Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer 10, 362 (2010).
  Article PubMed PubMed Central Google Scholar
• Dangles-Marie, V. et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 67, 398–407 (2007).
  Article CAS PubMed Google Scholar
• Guenot, D. et al. Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability. J. Pathol. 208, 643–652 (2006).
  Article CAS PubMed Google Scholar
• Fichtner, I. et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur. J. Cancer 40, 298–307 (2004).
  Article CAS PubMed Google Scholar
• Krumbach, R. et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur. J. Cancer 47, 1231–1243 (2011).
  Article CAS PubMed Google Scholar
• Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508–523 (2011).
  Article CAS PubMed Google Scholar
• Tentler, J. J. et al. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol. Cancer Ther. 9, 3351–3362 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Arcaroli, J. J. et al. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin. Cancer Res. 16, 4165–4177 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158–10163 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, M. P. et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protoc. 4, 1670–1680 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Fu, X., Guadagni, F. & Hoffman, R. M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc. Natl Acad. Sci. USA 89, 5645–5649 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Garrido-Laguna, I. et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br. J. Cancer 103, 649–655 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Rubio-Viqueira, B. et al. Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Mol. Cancer Ther. 6, 515–523 (2007).
  Article CAS PubMed Google Scholar
• Jimeno, A. et al. A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol. Cancer Ther. 9, 311–318 (2010).
  Article CAS PubMed Google Scholar
• Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311–1316 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Villarroel, M. C. et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther. 10, 3–8 (2011).
  Article CAS PubMed Google Scholar
• Jones, S. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic Cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548–4554 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bailey, J. M. et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 14, 5995–6004 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Yamazaki, S. et al. Pharmacokinetic-pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and anti-tumor efficacy in human tumor xenograft mouse models. J. Pharmacol. Exp. Ther. 340, 549–557 (2012).
  Article CAS PubMed Google Scholar
• Christensen, J. G. Proof of principle for crizotinib in anaplastic lymphoma kinase-positive malignancies was achieved in ALK-positive nonclinical models. Mol. Cancer Ther. 10, 2024 (2011).
  Article CAS PubMed Google Scholar
• Sasaki, T. et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71, 6051–6060 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ercan, D. et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29, 2346–2356 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Yoshida, T. et al. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci. 101, 167–172 (2010).
  Article CAS PubMed Google Scholar
• Dong, X. et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res. 16, 1442–1451 (2010).
  Article CAS PubMed Google Scholar
• Nemati, F. et al. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts. Anticancer Drugs 20, 932–940 (2009).
  Article CAS PubMed Google Scholar
• Cutz, J. C. et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin. Cancer Res. 12, 4043–4054 (2006).
  Article CAS PubMed Google Scholar
• Taetle, R. et al. Use of nude mouse xenografts as preclinical screens. Characterization of xenograft-derived melanoma cell lines. Cancer 60, 1836–1841 (1987).
  Article CAS PubMed Google Scholar
• Fiebig, H. H. et al. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics Proteomics 4, 197–209 (2007).
  CAS PubMed Google Scholar
• Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345–349 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Nemati, F. et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin. Cancer Res. 16, 2352–2362 (2010).
  Article CAS PubMed Google Scholar
• Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154–1157 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116–1127 (2008).
  Article CAS PubMed Google Scholar
• Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567–578 (2006).
  Article CAS PubMed Google Scholar
• Hennessey, P. T. et al. Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS ONE 6, e20584 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104, 973–978 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, J., Milo, G. E., Shuler, C. F. & Schuller, D. E. Xenograft growth and histodifferentiation of squamous cell carcinomas of the pharynx and larynx. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 81, 197–202 (1996).
  Article CAS PubMed Google Scholar
• Zatterstrom, U. K. et al. Growth of xenografted squamous cell carcinoma of the head and neck--possible correlation with patient survival. APMIS 100, 976–980 (1992).
  Article CAS PubMed Google Scholar
• Wennerberg, J., Trope, C. & Biorklund, A. Heterotransplantation of human head and neck tumours into nude mice. Acta Otolaryngol. 95, 183–190 (1983).
  Article CAS PubMed Google Scholar
• Langdon, S. P. et al. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann. Oncol. 5, 415–422 (1994).
  Article CAS PubMed Google Scholar
• Henriksson, E. et al. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol. 45, 300–305 (2006).
  Article CAS PubMed Google Scholar
• Peltonen, J. K. et al. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study. Head Neck Oncol. 3, 20 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Cabelguenne, A. et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J. Clin. Oncol. 18, 1465–1473 (2000).
  Article CAS PubMed Google Scholar
• Koch, W. M. et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J. Natl Cancer Inst. 88, 1580–1586 (1996).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov[online], (2011).
• US National Library of Medicine. ClinicalTrials.gov[online], (2012).
• US National Library of Medicine. ClinicalTrials.gov[online], (2012).
• Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492–2502 (2006).
  Article CAS PubMed Google Scholar
• Beckhove, P. et al. Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int. J. Cancer 105, 444–453 (2003).
  Article CAS PubMed Google Scholar
• de Plater, L. et al. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br. J. Cancer 103, 1192–1200 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514–1520 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Marangoni, E. et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 13, 3989–3998 (2007).
  Article CAS PubMed Google Scholar
• Moestue, S. A. et al. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 10, 433 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Laitinen, S., Karhu, R., Sawyers, C. L., Vessella, R. L. & Visakorpi, T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromosomes Cancer 35, 66–73 (2002).
  Article CAS PubMed Google Scholar
• Gray, D. R. et al. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res. 64, 1712–1721 (2004).
  Article CAS PubMed Google Scholar
• Grisanzio, C. et al. Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J. Pathol. 225, 212–221 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Yoshida, T. et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res. 65, 9611–9616 (2005).
  Article CAS PubMed Google Scholar
• Wang, Y. et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 64, 149–159 (2005).
  Article CAS PubMed Google Scholar
• Coppin, C., Kollmannsberger, C., Le, L., Porzsolt, F. & Wilt, T. J. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 108, 1556–1563 (2011).
  Article CAS PubMed Google Scholar
• Beniers, A. J. et al. Establishment and characterization of five new human renal tumor xenografts. Am. J. Pathol. 140, 483–495 (1992).
  CAS PubMed PubMed Central Google Scholar
• Kopper, L. et al. Renal cell carcinoma--xenotransplantation into immuno-suppressed mice. Oncology 41, 19–24 (1984).
  Article CAS PubMed Google Scholar
• Beroukhim, R. et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69, 4674–4681 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• An, Z., Jiang, P., Wang, X., Moossa, A. R. & Hoffman, R. M. Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin. Exp. Metastasis 17, 265–270 (1999).
  Article CAS PubMed Google Scholar
• Angevin, E. et al. Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosis. Lab. Invest. 79, 879–888 (1999).
  CAS PubMed Google Scholar
• Yuen, J. S. et al. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. Br. J. Cancer 104, 941–947 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hammers, H. J. et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol. Cancer Ther. 9, 1525–1535 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ellis, L. et al. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol. Cancer Ther. 11, 383–392 (2012).
  Article CAS PubMed Google Scholar
• Keunen, O. et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. USA 108, 3749–3754 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, J. et al. A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer 9, 465 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Carol, H. et al. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr. Blood Cancer 54, 707–715 (2010).
  PubMed PubMed Central Google Scholar
• Houghton, P. J. et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36, 393–403 (1995).
  Article CAS PubMed Google Scholar
• Vassal, G. et al. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int. J. Cancer 73, 156–163 (1997).
  Article CAS PubMed Google Scholar
• Houghton, P. J. et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer 49, 928–940 (2007).
  Article PubMed Google Scholar
• Foreman, N. K., Love, S. & Thorne, R. Intracranial ependymomas: analysis of prognostic factors in a population-based series. Pediatr. Neurosurg. 24, 119–125 (1996).
  Article CAS PubMed Google Scholar
• Merchant, T. E. et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J. Clin. Oncol. 22, 3156–3162 (2004).
  Article PubMed Google Scholar
• Pollack, I. F. et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 37, 655–666 (1995).
  Article CAS PubMed Google Scholar
• Yu, L. et al. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro. Oncol. 12, 580–594 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Zembutsu, H. et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62, 518–527 (2002).
  CAS PubMed Google Scholar
• Tan, A. C., Naiman, D. Q., Xu, L., Winslow, R. L. & Geman, D. Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics 21, 3896–3904 (2005).
  Article CAS PubMed Google Scholar
• Jimeno, A. et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res. 68, 2841–2849 (2008).
  Article CAS PubMed Google Scholar
• Messersmith, W. A. et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol. Cancer Ther. 8, 1484–1493 (2009).
  Article CAS PubMed Google Scholar
• Rajeshkumar, N. V. et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin. Cancer Res. 15, 4138–4146 (2009).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov[online], (2010).
• US National Library of Medicine. ClinicalTrials.gov[online], (2010).
• Singh, M. et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 28, 585–593 (2010).
  Article CAS PubMed Google Scholar
• Giovanella, B. C., Stehlin, J. S., Jr, Shepard, R. C. & Williams, L. J. Jr. Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer 52, 1146–1152 (1983).
  Article CAS PubMed Google Scholar
• Tentler, J. J. et al. Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin. Cancer Res. 16, 2989–2998 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Rajeshkumar, N. V. et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin. Cancer Res. 17, 2799–2806 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Song, D. et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol. Cancer Ther. 7, 3275–3284 (2008).
  Article CAS PubMed Google Scholar
• Merk, J., Rolff, J., Dorn, C., Leschber, G. & Fichtner, I. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur. J. Cardiothorac. Surg. 40, e29–e33 (2011).
  Article PubMed Google Scholar
• Hammer, S. et al. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin. Cancer Res. 16, 1452–1465 (2010).
  Article CAS PubMed Google Scholar
• Kolfschoten, G. M. et al. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol. Oncol. 76, 362–368 (2000).
  Article CAS PubMed Google Scholar
• Huynh, H., Soo, K. C., Chow, P. K., Panasci, L. & Tran, E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin. Cancer Res. 12, 4306–4314 (2006).
  Article CAS PubMed Google Scholar
• Huynh, H. et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 14, 6146–6153 (2008).
  Article CAS PubMed Google Scholar